Cuprior

RSS

trientine

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Cuprior. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Cuprior.

For practical information about using Cuprior, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 20/02/2023

Authorisation details

Product details
Name
Cuprior
Agency product number
EMEA/H/C/004005
Active substance
Trientine tetrahydrochloride
International non-proprietary name (INN) or common name
trientine
Therapeutic area (MeSH)
Hepatolenticular Degeneration
Anatomical therapeutic chemical (ATC) code
A16AX
Publication details
Marketing-authorisation holder
GMP-Orphan SA
Revision
6
Date of issue of marketing authorisation valid throughout the European Union
05/09/2017
Contact address
Pepiniere Paris Sante Cochin
27-29 rue du Faubourg Saint-Jacques
75014 Paris
France

Product information

17/08/2022 Cuprior - EMEA/H/C/004005 - R/0018

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Other alimentary tract and metabolism products

Therapeutic indication

Cuprior is indicated for the treatment of Wilson's disease in adults, adolescents and children ≥ 5 years intolerant to D-penicillamine therapy.

Assessment history

How useful was this page?

Add your rating
Average
3 ratings
2 ratings
1 rating
5 ratings